Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 25,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $72.52, for a total value of $1,813,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
G Bradley Cole also recently made the following trade(s):
- On Monday, August 12th, G Bradley Cole sold 60,000 shares of Genomic Health stock. The shares were sold at an average price of $73.31, for a total value of $4,398,600.00.
- On Tuesday, July 9th, G Bradley Cole sold 6,471 shares of Genomic Health stock. The shares were sold at an average price of $57.08, for a total value of $369,364.68.
NASDAQ:GHDX traded up $0.37 during trading hours on Wednesday, reaching $72.98. The company’s stock had a trading volume of 316,158 shares, compared to its average volume of 557,530. The stock has a 50 day moving average price of $72.85 and a two-hundred day moving average price of $65.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.74 and a current ratio of 5.74. The company has a market capitalization of $2.68 billion, a P/E ratio of 69.50 and a beta of 1.00. Genomic Health, Inc. has a 12 month low of $50.77 and a 12 month high of $92.18.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. increased its position in shares of Genomic Health by 166.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock worth $55,000 after purchasing an additional 493 shares in the last quarter. Manchester Capital Management LLC purchased a new position in Genomic Health during the 1st quarter worth $56,000. Point72 Asset Management L.P. purchased a new position in Genomic Health during the 2nd quarter worth $93,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Genomic Health by 29.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock worth $112,000 after buying an additional 441 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. increased its position in Genomic Health by 12.7% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,301 shares of the medical research company’s stock valued at $192,000 after buying an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 95.36% of the company’s stock.
GHDX has been the topic of a number of recent research reports. Barclays raised Genomic Health from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $45.00 to $72.00 in a research report on Tuesday, July 30th. Zacks Investment Research upgraded Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 price objective for the company in a report on Wednesday, July 31st. ValuEngine downgraded Genomic Health from a “buy” rating to a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. raised shares of Genomic Health from an “underweight” rating to a “neutral” rating and upped their price objective for the stock from $60.00 to $72.00 in a research note on Monday, July 29th. Finally, Deutsche Bank dropped their target price on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating on the stock in a report on Thursday, May 30th. Ten equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $69.86.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
See Also: How to build a Fibonacci channel
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.